Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients.

ABSTRACT:

Objectives

To evaluate the effectiveness and safety of upadacitinib in treatment-refractory inflammatory myositis.

Methods

Patients with refractory inflammatory myositis treated with upadacitinib from a single urban centre in Vancouver, British Columbia, Canada, were included from September 2020 to June 2023. The medical records of these patients were retrospectively reviewed.

Results

10 total patients were identified for review, including 5 classic dermatomyositis (DM), 3 amyopathic DM (ADM) and 2 antisynthetase syndrome. The patients failed an average of four immunosuppressants before initiation of upadacitinib. Three had prior Janus kinase inhibitor therapy with tofacitinib. In the classic DM and ADM aggregate group, upadacitinib offered clinically and statisticall

SUBMITTER: Beckett M 

PROVIDER: S-EPMC10806474 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature